false 0001506983 0001506983 2024-04-26 2024-04-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 26, 2024

 

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41141   98-0668934
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

301 Rte 17 North, Ste. 800, Rutherford, NJ   07070
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 842-7715

 

N/A

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   GCTK   The Nasdaq Stock Market LLC (Nasdaq Capital Market)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On April 26, 2024, Glucotrack, Inc., a Delaware corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following five proposals:

 

Proposal 1 – 2024 Equity Incentive Plan

 

The Company’s 2024 Equity Incentive Plan was approved. The final results of the voting were as follows:

 

Votes For  Votes Against   Abstentions   Broker Non-Votes 
9,989,257   885,365    5,163,149    1,932,226 

 

Proposal 2 – Election of Directors

 

Dr. Robert Fischell, Luis Malave, Andrew Sycoff, Shimon Rapps, Allen Danzig, and Erin Carter were each elected to serve on the Board of Directors (the “Board”) for a one-year term that expires at the 2025 Annual Meeting of Stockholders, or until their earlier death, resignation or removal and their successors are elected and qualified. The final results of the voting were as follows:

 

Director  Votes For   Votes Against   Abstentions   Broker Non-Vote 
Dr. Robert Fischell   10,793,666    134,682    5,109,423    1,932,226 
Luis Malave   10,793,666    122,745    5,121,360    1,932,226 
Andrew Sycoff   10,805,663    5,231,471    637    1,932,226 
Shimon Rapps   10,786,853    5,231,531    19,387    1,932,226 
Allen Danzig   10,793,726    122,685    5,121,360    1,932,226 
Erin Carter   10,793,806    122,745    5,121,220    1,932,226 

 

Proposal 3 – Reverse Stock Split

 

The Company’s stockholders approved of an amendment to Article IV of the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.001 per share at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board (the “Reverse Stock Split”) and with such Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion. The final results of the voting were as follows:

 

Votes For  Votes Against   Abstentions   Broker Non-Votes 
17,094,412   779,366    96,219     

 

Proposal 4 – Ratification of Independent Registered Public Accountant

 

The Company’s stockholders ratified the previous appointment by the Audit Committee of the Board of Fahn Kanne & Co. as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2023. The final results of the voting were as follows:

 

Votes For  Votes Against   Abstentions   Broker Non-Votes 
17,831,735   114,935    23,327     

 

Proposal 5 – Frequency of Non-Binding Advisory Votes on Executive Compensation

 

The Company’s stockholders indicated, on an advisory basis, the preferred frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers as follows:

 

Every

One (1) Year

 

Every

Two (2) Years

  

Every

Three (3) Years

   Abstentions 
2,213,593   531,688    8,138,410    5,154,080 

 

In light of the foregoing, the Company currently intends to hold an advisory vote on the compensation of its named executive officers every three (3) years until the next required advisory vote on the frequency of holding the advisory vote on named executive officer compensation.

 

ITEM 9.01 Exhibit

 

Exhibit 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 2, 2024  
   
  GLUCOTRACK, INC.
     
  By: /s/ Paul Goode
  Name: Paul Goode
  Title: Chief Executive Officer